Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil, +213

The Lancet

Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer +5

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, +27

New England Journal of Medicine

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, +166

The Lancet

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, +123

The Lancet

Hematological MalignancyMedicineImmunologyHematologyPharmacotherapy +4

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes, Laurie H. Sehn, Peter Johnson, +27

Journal of Clinical Oncology

Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Pau Montesinos, Christian Récher, Susana Vives, +13

New England Journal of Medicine

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N., +163

The Lancet

Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine +6

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Martin Schüler, Gopa Iyer, +103

The Lancet Oncology

Fgfr AlterationsMedicinePathologyAdvanced Solid TumoursFibroblast Growth Factor +5

Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia

Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, +23

American Journal of Hematology

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, +191

The Lancet

Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology +4